OcuLief
The Challenge
Our Solution – OcuLief™

Our aim is to overcome the current need for monthly injection of medicine to treat chronic eye diseases (e.g. AMD). OcuLief is tailored for the treatment of AMD, DR and DME by long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months.

In situ forming photo-crosslinked intravitreal OcuLief™ implant

Advantages of OcuLief™
  • Drug-loaded gels can be administered using conventional hypodermic needles (e.g. 27G or smaller)
  • Materials used in implant preparation are biocompatible & biodegradable
  • Allows localised drug delivery at various sites within and around the eye
  • Sustained and tailored drug delivery for up to 12 months
  • Ability to deliver wide range of molecules, including proteins and peptides
  • Simple and scalable formulation approach
    • Drug-loaded gels can be administered using conventional hypodermic needles (e.g. 27G or smaller)
    • Materials used in implant preparation are biocompatible & biodegradable
    • Allows localised drug delivery at various sites within and around the eye
    • Sustained and tailored drug delivery for up to 12 months
    • Ability to deliver wide range of molecules, including proteins and peptides
    • Simple and scalable formulation approach
    United Kingdom:
    T: +44 (0) 28 9097 5814
    E: info@re-vana.com

    USA:
    T: +1 (813) 323 1438
    E: mor.revana@gmail.com

    Mailing:
    McClay Research Centre
    97 Lisburn Road
    Belfast, BT9 7BL
    United Kingdom

    Re-Vana Therapeutics Inc.
    1027 South Dakota Ave
    Tampa, FL 33606
    USA